A critical assessment of docking programs and scoring functions.

PubWeight™: 5.78‹?› | Rank: Top 1%

🔗 View Article (PMID 17004707)

Published in J Med Chem on October 05, 2006

Authors

Gregory L Warren1, C Webster Andrews, Anna-Maria Capelli, Brian Clarke, Judith LaLonde, Millard H Lambert, Mika Lindvall, Neysa Nevins, Simon F Semus, Stefan Senger, Giovanna Tedesco, Ian D Wall, James M Woolven, Catherine E Peishoff, Martha S Head

Author Affiliations

1: GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, USA. Gregory.L.Warren@gsk.com

Articles citing this

(truncated to the top 100)

Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database. J Chem Inf Model (2010) 4.38

Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des (2013) 2.93

Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput Biol (2009) 2.84

Binding of small-molecule ligands to proteins: "what you see" is not always "what you get". Structure (2009) 2.83

Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J Comput Aided Mol Des (2007) 2.79

Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go. Br J Pharmacol (2007) 2.13

Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDock. J Cheminform (2009) 1.85

Target flexibility: an emerging consideration in drug discovery and design. J Med Chem (2008) 1.74

Structure-based virtual screening for drug discovery: a problem-centric review. AAPS J (2012) 1.68

What do we know and when do we know it? J Comput Aided Mol Des (2008) 1.68

CSAR benchmark exercise of 2010: selection of the protein-ligand complexes. J Chem Inf Model (2011) 1.61

Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists. PLoS One (2012) 1.60

Advances and challenges in protein-ligand docking. Int J Mol Sci (2010) 1.54

Variability in docking success rates due to dataset preparation. J Comput Aided Mol Des (2012) 1.54

Computational methods in drug discovery. Pharmacol Rev (2013) 1.51

Assessment of ligand-binding residue predictions in CASP9. Proteins (2011) 1.47

How to do an evaluation: pitfalls and traps. J Comput Aided Mol Des (2008) 1.43

CSAR benchmark exercise of 2010: combined evaluation across all submitted scoring functions. J Chem Inf Model (2011) 1.42

Accurate Prediction of Ligand Affinities for a Proton-Dependent Oligopeptide Transporter. Cell Chem Biol (2016) 1.42

Systematic analysis of genome-wide fitness data in yeast reveals novel gene function and drug action. Genome Biol (2010) 1.42

Prediction of protein-ligand binding affinity by free energy simulations: assumptions, pitfalls and expectations. J Comput Aided Mol Des (2010) 1.41

In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulators. PLoS Comput Biol (2007) 1.40

MedusaScore: an accurate force field-based scoring function for virtual drug screening. J Chem Inf Model (2008) 1.37

FRED and HYBRID docking performance on standardized datasets. J Comput Aided Mol Des (2012) 1.36

Blind docking of pharmaceutically relevant compounds using RosettaLigand. Protein Sci (2009) 1.35

Q-Dock: Low-resolution flexible ligand docking with pocket-specific threading restraints. J Comput Chem (2008) 1.34

FINDSITE: a combined evolution/structure-based approach to protein function prediction. Brief Bioinform (2009) 1.33

Optimization of CAMD techniques 3. Virtual screening enrichment studies: a help or hindrance in tool selection? J Comput Aided Mol Des (2008) 1.32

Comparative performance of several flexible docking programs and scoring functions: enrichment studies for a diverse set of pharmaceutically relevant targets. J Chem Inf Model (2007) 1.29

Predicting new indications for approved drugs using a proteochemometric method. J Med Chem (2012) 1.29

Surflex-Dock: Docking benchmarks and real-world application. J Comput Aided Mol Des (2012) 1.27

Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach. Chem Biol Interact (2006) 1.26

Assessment of programs for ligand binding affinity prediction. J Comput Chem (2008) 1.23

Bias, reporting, and sharing: computational evaluations of docking methods. J Comput Aided Mol Des (2007) 1.21

The SAMPL4 host-guest blind prediction challenge: an overview. J Comput Aided Mol Des (2014) 1.20

Validation of molecular docking programs for virtual screening against dihydropteroate synthase. J Chem Inf Model (2009) 1.19

Druggability Assessment of Allosteric Proteins by Dynamics Simulations in the Presence of Probe Molecules. J Chem Theory Comput (2012) 1.18

Limits of Free Energy Computation for Protein-Ligand Interactions. J Chem Theory Comput (2010) 1.18

Predicting P-glycoprotein-mediated drug transport based on support vector machine and three-dimensional crystal structure of P-glycoprotein. PLoS One (2011) 1.17

CSAR benchmark exercise 2011-2012: evaluation of results from docking and relative ranking of blinded congeneric series. J Chem Inf Model (2013) 1.17

More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules. Nat Struct Mol Biol (2014) 1.16

Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise. J Chem Inf Model (2013) 1.16

Docking flexible ligands in proteins with a solvent exposure- and distance-dependent dielectric function. J Comput Aided Mol Des (2010) 1.15

Virtual screening for novel COX-2 inhibitors using the ZINC database. Bioinformation (2008) 1.15

Assessment of ligand binding residue predictions in CASP8. Proteins (2009) 1.14

A statistical framework to evaluate virtual screening. BMC Bioinformatics (2009) 1.14

Ligand and structure-based models for the prediction of ligand-receptor affinities and virtual screenings: Development and application to the beta(2)-adrenergic receptor. J Comput Chem (2010) 1.13

Effects of protein conformation in docking: improved pose prediction through protein pocket adaptation. J Comput Aided Mol Des (2009) 1.11

Customizing scoring functions for docking. J Comput Aided Mol Des (2008) 1.11

Perspective: Alchemical free energy calculations for drug discovery. J Chem Phys (2012) 1.10

In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Res (2009) 1.08

QSAR: dead or alive? J Comput Aided Mol Des (2008) 1.07

MS-DOCK: accurate multiple conformation generator and rigid docking protocol for multi-step virtual ligand screening. BMC Bioinformatics (2008) 1.07

Identification of small-molecule inhibitors of ricin and shiga toxin using a cell-based high-throughput screen. Toxicon (2010) 1.06

Efficient incorporation of protein flexibility and dynamics into molecular docking simulations. Biochemistry (2011) 1.06

Docking screens: right for the right reasons? Curr Top Med Chem (2009) 1.05

Virtual screening using molecular simulations. Proteins (2011) 1.05

Improved ligand-protein binding affinity predictions using multiple binding modes. Biophys J (2010) 1.04

Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem (2009) 1.04

Optimal assignment methods for ligand-based virtual screening. J Cheminform (2009) 1.03

Novel inhibitors of anthrax edema factor. Bioorg Med Chem (2008) 1.03

A machine learning-based method to improve docking scoring functions and its application to drug repurposing. J Chem Inf Model (2011) 1.03

Evaluating docking programs: keeping the playing field level. J Comput Aided Mol Des (2008) 1.02

Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists. ChemMedChem (2011) 1.01

Conformational transitions upon ligand binding: holo-structure prediction from apo conformations. PLoS Comput Biol (2010) 1.01

Systematic exploitation of multiple receptor conformations for virtual ligand screening. PLoS One (2011) 0.99

Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening. J Med Chem (2013) 0.99

AMMOS: Automated Molecular Mechanics Optimization tool for in silico Screening. BMC Bioinformatics (2008) 0.99

Structure-based design of novel small-molecule inhibitors of Plasmodium falciparum. J Chem Inf Model (2010) 0.99

Inhibition of bacterial virulence: drug-like molecules targeting the Salmonella enterica PhoP response regulator. Chem Biol Drug Des (2012) 0.98

Molecular docking of intercalators and groove-binders to nucleic acids using Autodock and Surflex. J Chem Inf Model (2008) 0.98

Docking, virtual high throughput screening and in silico fragment-based drug design. J Cell Mol Med (2009) 0.98

Identifying unexpected therapeutic targets via chemical-protein interactome. PLoS One (2010) 0.97

Protein flexibility in docking and surface mapping. Q Rev Biophys (2012) 0.96

Importance of ligand reorganization free energy in protein-ligand binding-affinity prediction. J Am Chem Soc (2009) 0.96

Pushing the boundaries of 3D-QSAR. J Comput Aided Mol Des (2007) 0.96

Virtual screening applications: a study of ligand-based methods and different structure representations in four different scenarios. J Comput Aided Mol Des (2007) 0.95

Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: Correlation between antiprion activity and binding affinity. Antimicrob Agents Chemother (2008) 0.95

Survey of public domain software for docking simulations and virtual screening. Hum Genomics (2011) 0.95

Rationalizing tight ligand binding through cooperative interaction networks. J Chem Inf Model (2011) 0.95

Lead optimization mapper: automating free energy calculations for lead optimization. J Comput Aided Mol Des (2013) 0.94

Mechanism and energetics of charybdotoxin unbinding from a potassium channel from molecular dynamics simulations. Biophys J (2009) 0.94

Predicting the accuracy of protein-ligand docking on homology models. J Comput Chem (2011) 0.94

Protonation and pK changes in protein-ligand binding. Q Rev Biophys (2013) 0.94

New aryl hydrocarbon receptor homology model targeted to improve docking reliability. J Chem Inf Model (2011) 0.94

Exploring the role of receptor flexibility in structure-based drug discovery. Biophys Chem (2013) 0.93

Predicting drug metabolism: experiment and/or computation? Nat Rev Drug Discov (2015) 0.93

Identification of alternative binding sites for inhibitors of HIV-1 ribonuclease H through comparative analysis of virtual enrichment studies. J Chem Inf Model (2011) 0.93

An integrated suite of modeling tools that empower scientists in structure- and property-based drug design. J Comput Aided Mol Des (2015) 0.93

Exhaustive docking and solvated interaction energy scoring: lessons learned from the SAMPL4 challenge. J Comput Aided Mol Des (2014) 0.93

Can we use docking and scoring for hit-to-lead optimization? J Comput Aided Mol Des (2008) 0.93

Molecular dynamics simulations of GABA binding to the GABAC receptor: the role of Arg104. Biophys J (2008) 0.92

Modeling Protein-Ligand Binding by Mining Minima. J Chem Theory Comput (2010) 0.92

Specificity quantification of biomolecular recognition and its implication for drug discovery. Sci Rep (2012) 0.91

The marine cyanobacterial metabolite gallinamide A is a potent and selective inhibitor of human cathepsin L. J Nat Prod (2013) 0.91

Identification of new classes of ricin toxin inhibitors by virtual screening. Toxicon (2010) 0.90

Rapid calculation of protein pKa values using Rosetta. Biophys J (2012) 0.90

Using RosettaLigand for small molecule docking into comparative models. PLoS One (2012) 0.90

Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening. J Med Chem (2009) 0.89

Improving molecular docking through eHiTS' tunable scoring function. J Comput Aided Mol Des (2011) 0.89

Articles by these authors

Thousands of chemical starting points for antimalarial lead identification. Nature (2010) 8.28

Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. J Med Chem (2006) 3.85

Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell (2002) 3.13

Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature (2002) 3.11

Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J Biol Chem (2003) 2.28

Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob Agents Chemother (2002) 2.14

Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb Chem High Throughput Screen (2005) 1.99

Molecular shape and medicinal chemistry: a perspective. J Med Chem (2010) 1.91

Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity. Bioorg Med Chem Lett (2003) 1.90

Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci U S A (2010) 1.72

Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol (2002) 1.67

Activation of nuclear receptors: a perspective from structural genomics. Structure (2003) 1.59

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. J Med Chem (2003) 1.56

Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol Endocrinol (2005) 1.55

A structural basis for constitutive activity in the human CAR/RXRalpha heterodimer. Mol Cell (2004) 1.51

The Drosophila orphan nuclear receptor DHR38 mediates an atypical ecdysteroid signaling pathway. Cell (2003) 1.44

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J Med Chem (2002) 1.44

A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor. J Biol Chem (2005) 1.41

ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism. Nat Chem Biol (2007) 1.39

X-ray crystal structures of the estrogen-related receptor-gamma ligand binding domain in three functional states reveal the molecular basis of small molecule regulation. J Biol Chem (2006) 1.37

Blind docking of pharmaceutically relevant compounds using RosettaLigand. Protein Sci (2009) 1.35

Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J Virol (2004) 1.35

X-ray crystal structure of the liver X receptor beta ligand binding domain: regulation by a histidine-tryptophan switch. J Biol Chem (2003) 1.33

Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. J Med Chem (2012) 1.28

Determinants of cockroach and mouse exposure and associations with asthma in families and elderly individuals living in New York City public housing. Ann Allergy Asthma Immunol (2006) 1.24

Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. Chem Biol (2011) 1.20

The first completed genome sequence from a teleost fish (Fugu rubripes) adds significant diversity to the nuclear receptor superfamily. Nucleic Acids Res (2003) 1.20

Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram. J Mol Biol (2004) 1.19

Druggability Assessment of Allosteric Proteins by Dynamics Simulations in the Presence of Probe Molecules. J Chem Theory Comput (2012) 1.18

Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors. J Med Chem (2007) 1.18

Shedding of membrane proteins by ADAM family proteases. Essays Biochem (2002) 1.18

Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother (2002) 1.17

Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem (2004) 1.16

Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. Bioorg Med Chem Lett (2006) 1.15

Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers. Clin Cancer Res (2014) 1.13

Crystal structure of the kinase domain of serum and glucocorticoid-regulated kinase 1 in complex with AMP PNP. Protein Sci (2007) 1.11

Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors. J Med Chem (2008) 1.11

Validation studies of the site-directed docking program LibDock. J Chem Inf Model (2007) 1.11

Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration. Bioorg Med Chem Lett (2009) 1.10

Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol (2013) 1.09

Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1. J Med Chem (2008) 1.07

Bioinformatics and molecular modelling approaches to GPCR oligomerization. Curr Opin Pharmacol (2009) 1.04

Scientific competency questions as the basis for semantically enriched open pharmacological space development. Drug Discov Today (2013) 1.04

1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists. J Med Chem (2007) 1.02

2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels. Mol Pharmacol (2007) 0.98

Structure of Rev-erbalpha bound to N-CoR reveals a unique mechanism of nuclear receptor-co-repressor interaction. Nat Struct Mol Biol (2010) 0.97

Interactions that determine the assembly of a retinoid X receptor/corepressor complex. Proc Natl Acad Sci U S A (2002) 0.97

First X-ray cocrystal structure of a bacterial FabH condensing enzyme and a small molecule inhibitor achieved using rational design and homology modeling. J Med Chem (2003) 0.96

Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs. Bioorg Med Chem Lett (2006) 0.96

Perspectives on the discovery of small-molecule modulators for epigenetic processes. J Biomol Screen (2012) 0.94

Second generation of hydroxyethylamine BACE-1 inhibitors: optimizing potency and oral bioavailability. J Med Chem (2008) 0.92

1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists. J Med Chem (2010) 0.92

Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. J Med Chem (2007) 0.92

Azepanone-based inhibitors of human cathepsin L. J Med Chem (2005) 0.90

Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases. J Med Chem (2008) 0.90

Effectiveness of an integrated pest management intervention in controlling cockroaches, mice, and allergens in New York City public housing. Environ Health Perspect (2009) 0.90

Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity. J Med Chem (2007) 0.89

Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors. J Med Chem (2006) 0.89

Subtype specific effects of peroxisome proliferator-activated receptor ligands on corepressor affinity. Biochemistry (2003) 0.88

Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. Potency and chirality. J Med Chem (2002) 0.88

4-(1H-indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors. Bioorg Med Chem Lett (2008) 0.87

Design and synthesis of pyrrolidine-5,5'-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability. J Med Chem (2003) 0.87

Impact of jerry can disinfection in a camp environment - experiences in an IDP camp in Northern Uganda. J Water Health (2008) 0.87

Discovery of novel 3,5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases. Bioorg Med Chem Lett (2011) 0.86

Second generation of BACE-1 inhibitors part 2: Optimisation of the non-prime side substituent. Bioorg Med Chem Lett (2009) 0.86

Second generation of BACE-1 inhibitors part 3: Towards non hydroxyethylamine transition state mimetics. Bioorg Med Chem Lett (2009) 0.85

Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor. Bioorg Med Chem Lett (2010) 0.85

Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors. Bioorg Med Chem Lett (2006) 0.85

HIV-1 Env gp120 structural determinants for peptide triazole dual receptor site antagonism. Proteins (2012) 0.85

Modeling GPCR active state conformations: the β(2)-adrenergic receptor. Proteins (2011) 0.85

Identification of novel NK1/NK3 dual antagonists for the potential treatment of schizophrenia. Bioorg Med Chem Lett (2011) 0.84

Pyridine-3-carboxamides as novel CB(2) agonists for analgesia. Bioorg Med Chem Lett (2008) 0.84

Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors. Bioorg Med Chem Lett (2008) 0.83

BACE-1 inhibitors part 3: identification of hydroxy ethylamines (HEAs) with nanomolar potency in cells. Bioorg Med Chem Lett (2007) 0.83

Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists. J Med Chem (2010) 0.83

Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics. Bioorg Med Chem Lett (2009) 0.82

OOMMPPAA: a tool to aid directed synthesis by the combined analysis of activity and structural data. J Chem Inf Model (2014) 0.81

A ligand-specific kinetic switch regulates glucocorticoid receptor trafficking and function. J Cell Sci (2013) 0.81

Design and synthesis of orally bioavailable serum and glucocorticoid-regulated kinase 1 (SGK1) inhibitors. Bioorg Med Chem Lett (2009) 0.80

Optimization of pyrrolidinone based HIV protease inhibitors. Bioorg Med Chem Lett (2005) 0.80

Computer-aided molecular design under the SWOTlight. J Comput Aided Mol Des (2011) 0.80

Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPARγ partial agonist. Bioorg Med Chem Lett (2011) 0.80

6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem (2010) 0.80

Selective and dual action orally active inhibitors of thrombin and factor Xa. Bioorg Med Chem Lett (2007) 0.80

A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta. J Med Chem (2002) 0.80

New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems. Bioorg Med Chem Lett (2008) 0.79

The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs. Bioorg Med Chem Lett (2011) 0.79

Discovery of a novel class of PPARdelta partial agonists. Bioorg Med Chem Lett (2008) 0.79

1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors. J Med Chem (2010) 0.78

Modeling active GPCR conformations. Methods Enzymol (2013) 0.78

Oxa-azaspiro derivatives: a novel class of triple re-uptake inhibitors. ChemMedChem (2010) 0.78

Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists. Bioorg Med Chem Lett (2008) 0.78

G-protein-coupled receptor dynamics: dimerization and activation models compared with experiment. Biochem Soc Trans (2012) 0.78

Structure-activity relationships and in vivo activity of (1H-pyrazol-4-yl)acetamide antagonists of the P2X(7) receptor. Bioorg Med Chem Lett (2010) 0.78

Open data for drug discovery: learning from the biological community. Future Med Chem (2012) 0.78

New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems. Bioorg Med Chem Lett (2008) 0.78

3D QSAR in modern drug design. EXS (2003) 0.77

Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs. Bioorg Med Chem Lett (2011) 0.77